Kronox Lab Sciences Open Offer Sets ₹150.5 Crore Value

Open offer follows proposed promoter stake acquisition

Kronox Lab Sciences Limited has received a Draft Letter of Offer for a mandatory open offer from Indo Borax and Chemicals Limited and Zenrock Chemicals Private Limited. The offer seeks to acquire up to 95.7 lakh fully paid-up equity shares of Kronox Lab Sciences. At an offer price of ₹157.27 per share, the maximum consideration is ₹150.5 crore, assuming full acceptance. The shares offered represent 25.79% of Kronox Lab Sciences' voting share capital. IIFL Capital Services Limited is acting as the manager to the open offer. The transaction follows a Share Purchase Agreement under which Indo Borax is proposed to acquire a 64.26% stake from the sellers. The offer is being made by Indo Borax as the acquirer, with Zenrock Chemicals acting as a person acting in concert, or PAC. The open offer is required under the SEBI Takeover Regulations in connection with the proposed acquisition.

Draft Letter of Offer received by Kronox

Kronox disclosed receipt of the Draft Letter of Offer under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The Draft Letter of Offer was filed on September 4, 2026, and the company disclosed its receipt on September 5, 2026. The document has been filed with the Securities and Exchange Board of India, or SEBI, under the applicable takeover rules. It is intended to be disseminated through the stock exchange websites. The draft document states that SEBI has not approved the offer document. Shareholders should therefore distinguish the filing of the draft from regulatory approval of the offer. The Letter of Offer is expected to be sent to eligible public shareholders according to the stated schedule. The transaction remains subject to applicable statutory approvals and conditions under the Share Purchase Agreement.

Offer price and maximum consideration

The acquirer and PAC have offered ₹157.27 in cash for each Kronox Lab Sciences equity share tendered and accepted in the offer. The offer covers a maximum of 95,70,000 shares. The stated aggregate consideration is ₹150,50,73,900, or about ₹150.5 crore, if the entire offer is accepted. Each equity share has a face value of ₹10. The offer size has been calculated as 25.79% of the voting share capital, based on the capital specified in the offer documents. The price and share quantity are central terms for public shareholders assessing the tender offer. The offer documents also state that a ₹38 crore escrow has been deposited as part of the financial arrangements. This escrow amount is separate from the maximum offer consideration.

Key figures in the Kronox open offer

Tendering window runs from October 15

The tendering period is scheduled to begin on October 15, 2026, and close on October 29, 2026. During this period, eligible public shareholders may tender shares at the stated offer price of ₹157.27 per share. The last date for dispatch of the Letter of Offer to public shareholders is October 8, 2026. Indo Borax is scheduled to communicate acceptance or rejection of tendered shares by November 13, 2026. The tentative schedule in the Draft Letter of Offer extends to November 20, 2026. The dates remain linked to the regulatory process and other applicable clearances. Shareholders should refer to the final Letter of Offer and the tendering instructions for operational details. The announced dates provide the sequence for participation in the mandatory open offer.

Sequence of announcements and scheduled actions

Offer is not conditional on minimum acceptance

The Draft Letter of Offer states that this is not a conditional offer under Regulation 19 of the SEBI Substantial Acquisition of Shares and Takeovers Regulations. It is not subject to a minimum level of acceptance from shareholders. This means the offer does not require a specified minimum number of shares to be tendered for it to proceed on that basis. However, the offer remains subject to applicable regulatory approvals and statutory clearances. The documentation also refers to conditions contained in the Share Purchase Agreement. Non-resident shareholders may need to obtain Reserve Bank of India approvals where applicable. The offer materials note that participation and acceptance should be considered in line with the stated process and conditions. The final terms will be set out in the Letter of Offer issued under the SEBI takeover framework.

Why the transaction triggers takeover rules

SEBI's takeover regulations require an open offer in specified circumstances when an acquisition results in a substantial change in shareholding or control. The documents cite Regulations 3(1) and 4 of the SEBI Takeover Regulations as the basis for this open offer. The proposed 64.26% acquisition under the Share Purchase Agreement is the transaction that precedes the mandatory offer to public shareholders. The open offer gives public shareholders an opportunity to tender shares at the announced cash price. Indo Borax is a listed public company incorporated under the Companies Act, 1956. Kronox Lab Sciences is a listed company with its registered office in Vadodara, Gujarat. Zenrock Chemicals is identified in the documents as the PAC for the transaction. The structure places the proposed promoter stake acquisition and the public-shareholder offer within the SEBI takeover process.

What the filing means for shareholders

For Kronox Lab Sciences shareholders, the immediate relevant data points are the ₹157.27 offer price, the 95.7 lakh-share cap and the October 15 to October 29 tendering period. The maximum offer value of ₹150.5 crore reflects full acceptance of the shares sought under the offer. Since the offer has no minimum acceptance condition, shareholders are not required to collectively meet a threshold for the offer to proceed on that condition. Acceptance of tendered shares will be determined through the process stated in the offer documents. The Draft Letter of Offer is an important disclosure but is not an approval by SEBI. The final Letter of Offer and any updates to the timetable will remain important reference points. Shareholders, including non-residents where relevant, must consider the regulatory and procedural requirements set out in the documents.

Market and transaction context

The open offer formally sets out the route through which public shareholders can participate following the proposed transfer of a 64.26% stake. Its 25.79% size is based on Kronox Lab Sciences' voting share capital specified in the offer documents. The aggregate amount of ₹150.5 crore is derived from the offer price and the maximum number of shares sought. The offer price is payable in cash, according to the Draft Letter of Offer. The ₹38 crore escrow disclosed in the document forms part of the financial arrangements for the transaction. No minimum acceptance requirement reduces one condition that can apply to some offers, while approvals and contractual conditions still apply. The publication of the Detailed Public Statement on August 28 and the filing of the Draft Letter of Offer on September 4 mark key regulatory steps. The tendering window in October is the next scheduled shareholder-facing stage.

Next steps in the open offer process

Indo Borax and Zenrock Chemicals are scheduled to proceed with dispatch of the Letter of Offer by October 8, followed by the tendering window beginning October 15. Public shareholders will have until October 29 to tender shares under the announced terms. The acquirer is scheduled to communicate acceptance or rejection by November 13. The tentative timetable mentioned in the Draft Letter of Offer ends on November 20. All dates and actions remain subject to the regulatory process and applicable statutory approvals. Kronox Lab Sciences has disclosed the receipt of the draft document, while IIFL Capital Services continues as manager to the offer. The final Letter of Offer will set out the operative process for shareholders. Until then, the central announced terms remain the ₹157.27 price, the 25.79% offer size and the maximum ₹150.5 crore consideration.